Showing 1 – 20 of 645
Relevance | Newest | Oldest |
  • JAMA December 13, 2016

    Figure: Research Across Borders

    Cuban-US efforts target new cancer vaccine.
  • Research Across Borders

    Abstract Full Text
    JAMA. 2016; 316(22):2348-2348. doi: 10.1001/jama.2016.17140
  • Surgeon, Scientist, and Entrepreneur: One Man’s Fight Against Cancer

    Abstract Full Text
    JAMA. 2016; 316(13):1345-1347. doi: 10.1001/jama.2016.9304

    This Medical News story features a Q&A with physician-scientist and entrepreneur Patrick Soon-Shiong, MD, discussing the ‘cancer moonshot’ and promising approaches in cancer immunotherapy.

  • A Strategic Approach to Therapeutic Cancer Vaccines in the 21st Century

    Abstract Full Text
    JAMA. 2011; 305(22):2343-2344. doi: 10.1001/jama.2011.814
  • Beyond the Teachable Moment

    Abstract Full Text
    JAMA. 2007; 298(11):1326-1328. doi: 10.1001/jama.298.11.1326
  • Cancer Vaccine Research Inches Forward

    Abstract Full Text
    JAMA. 2004; 291(5):550-552. doi: 10.1001/jama.291.5.550
  • Upcoming Meetings

    Abstract Full Text
    JAMA. 1998; 280(17):1472-1472. doi: 10.1001/jama.280.17.1472-JFD80010-3-1
  • JAMA February 4, 2004

    Figure: Cancer Vaccine Research Inches Forward

    One cancer vaccine under study makes use of recombinant vaccinia virus containing genes for both tumor-associated antigen and costimulatory molecules (which increase immunogenicity). Cells infected with the attenuated vaccinia virus present tumor antigen on their surface. Antigen presentation (in the context of MHC 1) to resting T-lymphocytes and costimulation trigger a T-lymphocyte-mediated immune response, as opposed to a traditional antibody-mediated response.
  • Prostate Cancer Vaccine

    Abstract Full Text
    JAMA. 1998; 280(24):2067-2067. doi: 10.1001/jama.280.24.2067
  • 'Essential Components Now in Place' for Clinical Testing of Cancer Vaccine Strategies, Experts Say

    Abstract Full Text
    JAMA. 1995; 273(7):528-530. doi: 10.1001/jama.1995.03520310022019
  • Cancer Vaccine

    Abstract Full Text
    JAMA. 1967; 199(12):947-947. doi: 10.1001/jama.1967.03120120135036
  • CANCER VACCINE AND ANTICANCER GLOBULINS AS AN AID IN THE SURGICAL TREATMENT OF MALIGNANCY

    Abstract Full Text
    JAMA. 1914; LXIII(15):1258-1265. doi: 10.1001/jama.1914.02570150014004
  • JAMA July 9, 2014

    Figure: HPV Vaccine for Oropharyngeal Cancer?

  • Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of Condyloma

    Abstract Full Text
    free access has multimedia
    JAMA. 2014; 311(6):597-603. doi: 10.1001/jama.2014.95

    To investigate human papillomavirus (HPV) vaccine dose-level protection, Herweijer and coauthors examined the association between quadrivalent HPV vaccination and first occurrence of condyloma in relation to vaccine dose using data from Swedish population-based health registers for 1 045 165 females.

  • Two vs Three Doses of Human Papillomavirus Vaccine: New Policy for the Second Decade of the Vaccination Program

    Abstract Full Text
    JAMA. 2016; 316(22):2370-2372. doi: 10.1001/jama.2016.16393
  • The Diagnosis and Treatment of Prostate Cancer: A Review

    Abstract Full Text
    is active quiz
    JAMA. 2017; 317(24):2532-2542. doi: 10.1001/jama.2017.7248

    This review summarizes advances in risk classification methods, imaging techniques, biomarkers for diagnosis, and treatments for prostate cancer.

  • Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women

    Abstract Full Text
    free access
    JAMA. 2016; 316(22):2411-2421. doi: 10.1001/jama.2016.17615

    This noninferiority trial compares human papillomavirus (HPV) type–specific antibody responses among girls and boys aged 9 to 14 years given 2 doses of HPV vaccine vs adolescent girls and young women aged 16 to 26 years given 3 doses.

  • HPV Vaccine for Oropharyngeal Cancer?

    Abstract Full Text
    JAMA. 2014; 312(2):122-122. doi: 10.1001/jama.2014.7061
  • JAMA April 25, 2017

    Figure 2: Time to Colonoscopy After a Positive FIT and Adjusted Riska of Advanced Adenoma, Any Colorectal Cancer, and Advanced-Stage Colorectal Cancer

    BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); FIT, fecal immunochemical test; OR, odds ratio. Models for any colorectal cancer include the entire population. Advanced adenoma was defined as adenomas with advanced histology (ie, tubulovillous and villous adenomas). Models for advanced adenoma exclude 2191 patients diagnosed with colorectal cancer. Advanced-stage cancers were defined as stage III (regional lymph node involvement) or stage IV (distant metastasis) according to the American Joint Committee on Cancer staging system or, for those without such staging, as code 3 (disease in the regional lymph nodes), code 4 (regional disease with direct extension and spread to the regional lymph nodes), or code 7 (distant metastasis) according to the 2013 Surveillance, Epidemiology, and End Results Program Coding and Staging Manual. Models for advanced-stage colorectal cancer exclude 14 patients with colorectal cancer of unknown stage. The adjusted advanced-stage colorectal cancer model dropped 244 patients with unknown BMI because no patient with unknown BMI had this outcome. aAdjusted for sex; age; race/ethnicity; BMI; region; FIT screening year; completion of previous FIT screening (ever and in the prior year); and in the year prior to FIT screening, receipt of the flu or pneumonia vaccine, presence of gastrointestinal symptoms (bleeding or blood in stool, unexplained weight loss, abdominal pain, diarrhea, diverticulitis, inflammatory bowel disease, or Lynch syndrome), diagnosis of iron-deficiency anemia or diabetes, current smoker, number of primary care visits, and number of days hospitalized.bRates (95% CIs) were per 1000 patients who had a colonoscopy after a positive FIT.